• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[一名重症监护患者发生的伴有血栓形成的Ⅱ型肝素诱导的血小板减少症:使用直接凝血酶抑制剂阿加曲班的治疗管理]

[Heparin-induced thrombocytopenia type II with thrombosis in an intensive care patient: therapy management using the direct thrombin inhibitor argatroban].

作者信息

Heil S

机构信息

Abteilung für Anästhesie und Intensivmedizin, Wilhelminenspital, Montleartstrasse 37, 1160, Wien, Osterreich.

出版信息

Anaesthesist. 2009 Nov;58(11):1119-22. doi: 10.1007/s00101-009-1624-y.

DOI:10.1007/s00101-009-1624-y
PMID:19795099
Abstract

Heparin-induced thrombocytopenia (HIT) type II is a life-threatening complication of heparin therapy. The present case report describes the therapeutic management of HIT type II with thrombosis using the direct thrombin inhibitor argatroban in an intensive care patient after successful surgery of a ruptured infrarenal abdominal aortic aneurysm. Despite high dosing and long-term application of argatroban, anticoagulation remained uncritical and was well controllable by monitoring the activated partial thromboplastin time. In consideration of the pharmacological characteristics, therapy suspension due to invasive interventions and switching to an oral vitamin K antagonist by defined algorithm resulted in an effective management.

摘要

II型肝素诱导的血小板减少症(HIT)是肝素治疗的一种危及生命的并发症。本病例报告描述了一名肾下腹主动脉瘤破裂成功手术后的重症监护患者,使用直接凝血酶抑制剂阿加曲班治疗II型HIT并伴有血栓形成的情况。尽管高剂量且长期应用阿加曲班,但抗凝情况并不危急,通过监测活化部分凝血活酶时间可很好地控制。考虑到药物特性,因侵入性干预而暂停治疗,并按照既定算法改用口服维生素K拮抗剂,从而实现了有效的治疗管理。

相似文献

1
[Heparin-induced thrombocytopenia type II with thrombosis in an intensive care patient: therapy management using the direct thrombin inhibitor argatroban].[一名重症监护患者发生的伴有血栓形成的Ⅱ型肝素诱导的血小板减少症:使用直接凝血酶抑制剂阿加曲班的治疗管理]
Anaesthesist. 2009 Nov;58(11):1119-22. doi: 10.1007/s00101-009-1624-y.
2
The use of argatroban for carotid endarterectomy in heparin-induced thrombocytopenia.阿加曲班在肝素诱导的血小板减少症患者颈动脉内膜切除术中的应用。
Anesth Analg. 2005 Apr;100(4):946-948. doi: 10.1213/01.ANE.0000146940.47989.5F.
3
A randomized, open-label pilot study comparing desirudin and argatroban in patients with suspected heparin-induced thrombocytopenia with or without thrombosis: PREVENT-HIT Study.一项比较达肝素和阿加曲班在伴有或不伴有血栓形成的肝素诱导血小板减少症患者中的随机、开放标签的初步研究:PREVENT-HIT 研究。
Am J Ther. 2011 Jan;18(1):14-22. doi: 10.1097/MJT.0b013e3181f65503.
4
Effects of argatroban therapy, demographic variables, and platelet count on thrombotic risks in heparin-induced thrombocytopenia.阿加曲班治疗、人口统计学变量及血小板计数对肝素诱导的血小板减少症血栓形成风险的影响
Chest. 2006 Jun;129(6):1407-16. doi: 10.1378/chest.129.6.1407.
5
Reducing harm associated with anticoagulation: practical considerations of argatroban therapy in heparin-induced thrombocytopenia.降低抗凝相关危害:阿加曲班治疗肝素诱导的血小板减少症的实际考量
Drug Saf. 2009;32(3):203-18. doi: 10.2165/00002018-200932030-00003.
6
Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia.阿加曲班用于肝素诱导的血小板减少症患者的抗凝治疗。
Circulation. 2001 Apr 10;103(14):1838-43. doi: 10.1161/01.cir.103.14.1838.
7
Argatroban anticoagulation for heparin-induced thrombocytopenia in elderly patients.阿加曲班用于老年肝素诱导的血小板减少症患者的抗凝治疗。
Drugs Aging. 2007;24(6):489-99. doi: 10.2165/00002512-200724060-00005.
8
[Patient with heparin-induced thrombocytopenia type II and implanted left ventricular assist device].[患有II型肝素诱导的血小板减少症并植入左心室辅助装置的患者]
Anaesthesist. 2008 Jan;57(1):49-52. doi: 10.1007/s00101-007-1297-3.
9
Argatroban therapy for heparin-induced thrombocytopenia in acutely ill patients.阿加曲班治疗急性病患者肝素诱导的血小板减少症。
Clin Appl Thromb Hemost. 2007 Oct;13(4):353-61. doi: 10.1177/1076029607303617.
10
Heparin-induced thrombocytopenia in patients administered heparin solely for hemodialysis.仅接受肝素进行血液透析的患者发生肝素诱导的血小板减少症。
Ren Fail. 2006;28(7):537-9. doi: 10.1080/08860220600843813.

本文引用的文献

1
Argatroban for anticoagulation in continuous renal replacement therapy.阿加曲班在连续性肾脏替代治疗中的抗凝作用
Crit Care Med. 2009 Jan;37(1):105-10. doi: 10.1097/CCM.0b013e3181932394.
2
Influence of direct thrombin inhibitor argatroban on coagulation assays in healthy individuals, patients under oral anticoagulation therapy and patients with liver dysfunction.直接凝血酶抑制剂阿加曲班对健康个体、接受口服抗凝治疗的患者及肝功能不全患者凝血检测的影响
Blood Coagul Fibrinolysis. 2008 Jun;19(4):288-93. doi: 10.1097/MBC.0b013e3282fe73ec.
3
[Direct thrombin inhibitors: pharmacology and application in cardiovascular anesthesia].
[直接凝血酶抑制剂:药理学及在心血管麻醉中的应用]
Anaesthesist. 2008 Jun;57(6):597-606. doi: 10.1007/s00101-008-1347-5.
4
Argatroban anticoagulation in critically ill patients.阿加曲班在危重症患者中的抗凝作用。
Ann Pharmacother. 2007 May;41(5):749-54. doi: 10.1345/aph.1H569. Epub 2007 Apr 17.
5
Think of HIT.想想医院获得性感染(HIT)。 (注:因原文简短,推测此处HIT可能是“Hospital-Acquired Infection”的缩写,具体需结合上下文确定准确含义)
Hematology Am Soc Hematol Educ Program. 2006:408-14. doi: 10.1182/asheducation-2006.1.408.
6
Evaluation of pretest clinical score (4 T's) for the diagnosis of heparin-induced thrombocytopenia in two clinical settings.在两种临床环境中评估用于诊断肝素诱导的血小板减少症的预测试临床评分(4T's)。
J Thromb Haemost. 2006 Apr;4(4):759-65. doi: 10.1111/j.1538-7836.2006.01787.x.
7
[Argatroban: pharmacological properties and anaesthesiological aspects].[阿加曲班:药理特性及麻醉学方面]
Anaesthesist. 2006 Apr;55(4):443-50. doi: 10.1007/s00101-005-0962-7.
8
A critical evaluation of assays for detecting antibodies to the heparin-PF4 complex.对检测肝素-PF4复合物抗体的检测方法的批判性评估。
Semin Thromb Hemost. 2004 Jun;30(3):359-68. doi: 10.1055/s-2004-831049.
9
Transition from argatroban to oral anticoagulation with phenprocoumon or acenocoumarol: effects on prothrombin time, activated partial thromboplastin time, and Ecarin Clotting Time.从阿加曲班转换为使用苯丙香豆素或醋硝香豆素进行口服抗凝治疗:对凝血酶原时间、活化部分凝血活酶时间和蛇毒凝血时间的影响。
Thromb Haemost. 2004 Jun;91(6):1137-45. doi: 10.1160/TH03-12-0794.
10
Treatment of heparin-induced thrombocytopenia: a critical review.肝素诱导的血小板减少症的治疗:一项批判性综述。
Arch Intern Med. 2004 Feb 23;164(4):361-9. doi: 10.1001/archinte.164.4.361.